Nurandociguat vs SK-08

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Soluble guanylate cyclase · full Chronic Kidney Disease pipeline

Nurandociguat

Developed by Bayer

Phase 2 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT06522997 · Phase 2 · completed

The study used random assignment, quadruple masking, and a placebo control with a large enrollment of 1,222 participants. Its primary endpoint was the surrogate measure of change in UACR, and the primary comparison cannot yet be judged because results are not posted.

No aligned efficacy figure on record for this race.

SK-08

Developed by Consun Pharmaceutical Group

Phase 1 in Chronic Kidney Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNurandociguatSK-08
Kidney composite outcome—Not reported—Not reported
UACR, % change—Not reported—Not reported
eGFR slope—Not reported—Not reported
Haemoglobin, change—Not reported—Not reported

Kidney composite outcome

Nurandociguat
—Not reported
SK-08
—Not reported

UACR, % change

Nurandociguat
—Not reported
SK-08
—Not reported

eGFR slope

Nurandociguat
—Not reported
SK-08
—Not reported

Haemoglobin, change

Nurandociguat
—Not reported
SK-08
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Nurandociguat: no structured comparison results are available for Chronic Kidney Disease.

SK-08: no structured comparison results are available for Chronic Kidney Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nurandociguat's landscape · SK-08's landscape